Abstract: PAX8 is a nephric-lineage transcription factor and is a crucial transcription factor for organogenesis of the thyroid gland, kidney, and Mu¨llerian system. PAX8 is shown to be expressed in a high percentage of kidney and ovarian carcinomas. Limited information is known about the specificity of PAX8 in various neoplastic tumors. This comprehensive study examines the immunohistochemical expression of PAX8 in multiple normal and neoplastic tissues including renal cell carcinoma and ovarian cancers. Renal cell carcinomas stained positive for PAX8 in 90% (110 of 122) of the cases and 100% of normal kidney stained PAX8 positive. In all cases of ovarian cancers 79% (181 of 229) expressed PAX8, and in thyroid cancer, PAX8 was expressed in 90% (9 of 10) cases. In endometrial cancers, 84% (113 of 134) of the cases were positive and in cervical cancer, 98% (1 of 60) squamous cell carcinomas cases were negative and 83% (5 of 6) cervical adenocarcinomas were positive. In bladder cancers, 93% of all the cases were negative including all bladder adenocarcinomas. PAX8 expression was observed in only one case of lung cancer (99% negative) and was 100% negative in cancers of the colon, breast, prostate, liver, testicular, stomach, esophagus, melanoma, gastrointestinal stromal tumors, leiomyosarcoma, and pheochromocytoma. The PAX8 specificity has been demonstrated in over 1100 cases of normal and neoplastic tissues. PAX8 is a specific and sensitive marker for renal cell and ovarian carcinomas and should be a valuable addition to the histopathology laboratory.
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Key Words: PAX8, immunohistochemistry, renal cell carcinoma, ovarian cancer (Appl Immunohistochem Mol Morphol 2011;19:293-299) P ax genes are a family of cell-lineage transcription factors that play fundamental roles during organogenesis and are regulatory proteins expressed in embryonic or neoplastic cells of the same lineage. PAX8 is a nephric-lineage transcription factor which is a crucial transcription factor for the organogenesis of the thyroid gland, kidney, and Mu¨llerian system. These proteins are required for cell growth and differentiation in embryonic tissues and can be expressed in adult tissues in specific cell-lineage neoplastic tissues. [1] [2] [3] [4] [5] [6] Recently PAX8 has been shown to be expressed in a high percentage of kidney and ovarian carcinomas. [4] [5] [6] Limited information is known about the specificity of PAX8 in various neoplastic tumors. This detailed study examines the immunohistochemical expression of PAX8 in multiple normal and neoplastic tissues.
MATERIALS AND METHODS
Human formalin-fixed paraffin-embedded tissue microarrays (TMAs) were both constructed in-house and commercially purchased (US Biomax and Pantomics). TMAs included both normal and neoplastic tissues including kidney, bladder, prostate, lung, breast, colon, liver, pancreas, uterus, cervix ovary, testis, brain, stomach, esophagus, melanoma, sarcomas, and lymphoma. Tissue sections were cut at 4 to 5 m (5 mm) thickness and dried for 30 to 60 minutes at 601C. Slide were deparaffinized in Slide Brite (Biocare Medical) and hydrated in a series of graded alcohols to water. Tissues were treated with 3% H 2 O 2 in buffer and placed into a modified citrate buffer (DIVA, Biocare Medical), and then placed into a Decloaking Chamber (antigen retrieval unit, Biocare Medical) and heated to 1251C for 30 minutes. Tissues were then allowed to cool for 10 minutes, and then rinsed in deionized water.
Immunohistochemistry
The PAX8 rabbit polyclonal antibody (Biocare Medical) was titrated at 1:500 in Renoir Red Diluent (Biocare Medical) and incubated for 30 minutes. Tissues were rinsed in tris buffered saline wash buffer and incubated in a biotin-free goat antirabbit detection system (MACH 2, Biocare Medical) for 30 minutes; tissues were then visualized with diaminobenzidine. Slides were briefly counterstained (5 s) in a modified Mayer's hematoxylin. Tumors were considered positive for PAX8, if more than 5% of the tumor nuclei and/or if strong focal staining was observed.
RESULTS
A summary of the overall PAX8 staining percentage for all cancers types is presented in Table 1 . Renal cell carcinoma (RCC) and ovarian cancer were subcategorized by diagnosis (Table 2) . Diagnostic types for all other cancers were also divided into subgroups and assessed for positive and negative staining (Table 3) .
RCC
All RCCs stained positive in 90% (110 of 122) of the cases (Table 1) . Normal kidney stain positive for PAX8 in all cases. In clear cell RCC, PAX8 expression was observed in 91% (86 of 94), in 100% (8 of 8) metastatic (Figs. 2A-C) .
Other Cancers
In thyroid cancer, PAX8 was expressed in 90% (9 of 10) of the cases (Figs. 3A, B) , and in 13 of 32 of medullary thyroid cancers (Table 3) . In endometrial cancer, 84% (113 of 134) were positive (Tables 1 and 3) (Fig. 4A) . In cervical cancer; 98% (59 of 60) of squamous cell carcinoma cases were negative and 83% (5 of 6) of cervical adenocarcinomas were positive (Fig. 4B) . In bladder cancer, Tong et al 6 noted that 23% (4 of 17) of urothelial carcinomas of the pelvis region were positive for PAX8 and that 0% (0 of 40) were negative for urothelial carcinomas of the urinary bladder. In this study, 93% of the cases of urothelial carcinomas were negative for PAX8. The commercially made TMA did not distinguish between urothelial carcinomas of the bladder and urothelial carcinomas of the renal pelvis and ureter. Islets of Langerhans cells in normal pancreas stained positive for PAX8 (Fig. 5A) , and was positive in 16% (4 of 24) of pancreatic adenocarcinomas tumors. (Figs . 5B, C) ( Tables 1 and 3 ). In both normal lymphoid and lymphoma tissues, PAX8 appears to be expressed in B and B-cell lineage tumors (data not shown); thus normal lymphoid tissue can serve as positive internal control. This may explain why chronic inflammatory conditions such as chronic cystitis are positive for PAX8.
In rectal cancers, all adenocarcinomas were negative and one rectal carcinoid was positive (Tables 1 and 3) . PAX8 expression was observed in only one case of lung cancer (99% negative) and was 100% negative in cancers of the colon, breast, prostate, liver, testicular, stomach, and esophagus cancers. PAX8 was also negative in melanoma, gastrointestinal stromal tumors, leiomyosarcoma, and pheochromocytoma; interestingly (2 of 5) of rhabdomyosarcoma cases stained positive for PAX8 (Table 3) .
Normal Tissue (Federal Drug Administration 33 Tissue Type for Cross-reactivity)
In normal tissues (Table 4) , PAX8 expression was observed in cerebellum, spleen, lymph node, thymus, tonsil, thyroid, fallopian tube, kidney, uterus, pancreas, and urethra. Normal ovary was negative for PAX8. In points of interest, PAX8 staining was detected in the epithelial cells of the proximal and distal renal tubules, loops of Henle, collecting ducts, and the parietal epithelial cells of Bowman's capsule. PAX8 staining was also detected in the lining of the upper urethra, and B cells were observed in all lymphatic tissues. In normal thyroid, PAX8 expression was observed in follicle cells. In pancreas, cells in the islets of Langerhans were stained positive, and in normal uterus, PAX8 staining was expressed in the endometrial mucosa.
DISCUSSION
PAX2 and PAX8 are nephric-lineage transcription factors and are required for the establishment of renal lineage cells and the formation of the kidney. 6 In a study by Mazal et al, 7 PAX-2 expression was found in the majority of clear cell RCCs (88%), but only in few papillary RCCs, chromophobe RCCs, and oncocytomas; however, in contrast to PAX2, the specificity and sensitivity of PAX8, especially in various neoplastic tissues is not completely known. 6 In this detailed study, we have demonstrated that PAX8 is a sensitive marker for RCCs, ovarian cancers, thyroid cancers, and endometrial adenocarcinomas. Most other types of cancers were 100% negative. The advantage of PAX8 versus other markers, such as RCC marker and CD10, is that PAX8 staining is localized to the nucleus and is less prone to false negatives by nonspecific background, endogenous pigments, or endogenous biotin background.
RCC
In the past, panels of antibodies used for diagnosing RCC included CD10, RCC marker, kidney-specific cadherin, CK7, and vimentin; however, these antibodies either lack sensitivity and/or specificity and gave negative staining for certain renal carcinoma subgroups. [8] [9] [10] [11] [12] [13] PAX2 is relative new marker and has shown to be fairly specific for some RCC. 6, 7 In our study, PAX8 stained 90% of all RCCs and stained 91% of clear cell RCCs, and 100% (14 of 14) of papillary ( Table 2 ). This concurred closely with Tong et al. 6 In some cases, assessment of PAX8 may be difficult, if the hematoxylin counterstain was too dark; therefore, we recommend a very light hematoxylin counterstain to ensure the accuracy of positive stained cells. Approximately 25% of the cases of clear cell RCC expressed 1 to 2+ staining. In our study, we did not include any renal cell oncocytomas; however, Tong et al 6 demonstrated PAX8 expression in 21 of 22 (95%) of oncocytomas.
Ovarian Cancer
In this study, we tested 245 cases of ovarian cancer. PAX8 was expressed in 79% of all cases. More significantly, in the 2 most common ovarian cancers, 88% were positive and 97% (31 of 32) of metastatic ovarian cancers also expressed PAX8 (Tables 1 and 2 ). PAX8 was also positive in 41% (27 of 54) mucinous cystadenocarcinoma. PAX8 was also negative in 100% of the 100 cases of breast cancer (Tables 1 and 2 ). In a previous study by Nonaka, 4 PAX8 reaction was found in 108 of 124 ovarian carcinomas (87%) including 81 of 84 serous papillary carcinomas (96%), 16 of 18 endometrioid carcinomas (89%), 10 of 10 clear cell carcinomas (100%); PAX8 was also found negative in 243 cases of breast cancer. Our study had very similar results and thus collaborates well with the Nonaka study. Compared with the past, antibody panels had consisted mainly of CA125, WT1, and CK7; however, limitations with regard to specificity and sensitivity have been described. [14] [15] [16] [17] [18] The addition of PAX8 should be added to this panel and will prove to be a valuable addition especially in diagnosis of tumors of unknown origin. 
Thyroid Cancer
In 10 papillary thyroid carcinoma cases, 90% (9 of 10) expressed strong staining (Table 3 ). In a study by Nonaka, 2 PAX8 was expressed in papillary carcinomas, follicular adenomas/carcinomas, and in poorly differentiated carcinomas in a diffuse manner, whereas PAX8 expression in medullary carcinomas was variable. PAX8 was expressed in 79% of anaplastic carcinomas to a variable extent, whereas TTF-1 stained 18% of anaplastic carcinomas. Our study also demonstrated variable expression of PAX8 in thyroid medullary carcinoma (13 of 32 cases; Table 3 ).
Endometrial Cancer
At present, there have been no extensive immunohistochemistry studies evaluating PAX8 in endometrial adenocarcinomas. In our study, PAX8 expression was observed in 84% (113 of 134) of the endometrial adenocarcinomas (Table 3 ). An immunohistochemistry panel of ER/PR (+), vimentin (+), CK8/18 (+), and CEAm (À) with PAX8 (+) may be added to the profile for identifying endometrial adenocarcinomas. 19 
Other Cancers
Breast, colon, lung, and prostate cancer were virtually 100% negative for PAX8. Other studies which included 243 breast cancer cases were 100% negative for PAX8 and thus PAX8 proved to be a useful marker in the differential diagnosis of ovarian and breast carcinomas.
4 PAX8 also appears to be superior to WT1 for the diagnosis of all types of nonmucinous ovarian carcinomas, notably clear cell and endometrioid types where WT1 expression is generally negative. 4 PAX8 stained thyroid cancers, islets of Langerhans, a subset of pancreatic tumors, and one rectal carcinoid. PAX proteins have been shown to play an important role in islet cell differentiation. 20 In our study, we had limited cases of pancreatic cancers and other neuroendocrine tumors (Table 3) ; therefore, further evaluation is needed in this area.
CONCLUSIONS
In summary, PAX8 specificity and sensitivity were demonstrated in over 1100 cases of normal and neoplastic tissues, in 19 different major cancer types and their subtypes, and in 33 different normal tissues. PAX8 proved to be fairly specific and a sensitive marker for renal cell and ovarian carcinomas and should be recommended for use in a clinical histopathology laboratory setting. 
